The grades of 10 pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
Intra-Cellular Therapies, Inc. (ITCI) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, ITCI also gets A’s. For more information, get Portfolio Grader’s complete analysis of ITCI stock.
NuPathe Inc. (PATH) shows solid improvement this week. The company’s rating rises from a C to a B. NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. For more information, get Portfolio Grader’s complete analysis of PATH stock.
This week, Zoetis, Inc. Class A (ZTS) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. For more information, get Portfolio Grader’s complete analysis of ZTS stock.
This week, Novo Nordisk A/S Sponsored ADR Class B (NVO) pushes up from a C to a B rating. Novo Nordisk develops, produces, and markets pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of NVO stock.
Watson Pharmaceuticals (WPI) improves from a B to an A rating this week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
This week, Taro Pharmaceutical’s (TARO) ratings are up from a B last week to an A. Taro Pharmaceutical Industries is engaged in developing, manufacturing, and marketing prescription and over-the-counter pharmaceutical products, as well as active pharmaceutical ingredients in the United States, Canada and Israel. For more information, get Portfolio Grader’s complete analysis of TARO stock.
Corcept Therapeutics Incorporated.’s (CORT) ratings are looking better this week, moving up to a B from last week’s C. Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. For more information, get Portfolio Grader’s complete analysis of CORT stock.
Sagent Pharmaceuticals, Inc. (SGNT) boosts its rating from a C to a B this week. Sagent Pharmaceuticals is an injectable pharmaceutical company. For more information, get Portfolio Grader’s complete analysis of SGNT stock.
Novartis AG Sponsored ADR (NVS) gets a higher grade this week, advancing from a B last week to an A. Novartis manufactures pharmaceutical and consumer healthcare products. The current dividend yield is 2.8%. For more information, get Portfolio Grader’s complete analysis of NVS stock.
Bristol-Myers Squibb Company (BMY) improves from a C to a B rating this week. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of BMY stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
